Announced
Completed
Financials
Tags
United States
molecules platform
Majority
Completed
Friendly
Health Care Services
Single Bidder
Private Equity
Private
Acquisition
Domestic
Synopsis
MPM Capital led a $75m Series A round in Photys Therapeutics, a developer of phosphorylation-inducing chimeric small molecule medicines, with participation of Omega Funds, Longwood, 8VC, Arkin Bio, Mass General Brigham Ventures, MRL Ventures Fund, Merck, Eli Lilly, and Heritage Medical Systems. “Many current chimeric and bifunctional modalities focus on protein degradation, which limits their range of addressable diseases. Photys expands this functionality, using PHICS to recruit kinases and induce phosphorylation, a key post-translational modification that controls many protein functions, including activation, stabilization, localization, trafficking, degradation, and inactivation," Edward Holson, Photys Co-Founder and Chief Scientific Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.